Immunic reported a net loss of $42.3 million for the third quarter ended September 30, 2026, as the company ramps up clinical activities and pre-commercialization readiness. The company ended the period with $132.0 million in cash and cash equivalents, which is projected to provide a capital runway into late 2027.
Key Highlights
- Top-line data for the pivotal Phase 3 ENSURE trials in relapsing multiple sclerosis remains on track for December 2026 release.
- Research and development expenses increased to $23.9 million, driven by a $2.9 million rise in NDA readiness activities and higher drug supply costs.
- General and administrative expenses reached $19.4 million, primarily due to $11.0 million in personnel cost increases including non-cash stock compensation related to a separation agreement.